Immplacate

IMMPLACATE is a preclinical stage cell therapy company. To our knowledge, we are the first company to clinically develop educated mesenchymal cells (EMCs) for treatment of unwanted immune responses. Patients with acute and chronic immune disorders can have an increased risk of death and a reduced quality of life. To make matters worse, current pharmaceutical options can have toxic side effects and put patients at risk for life-threatening infections. This means that physicians are not only managing their patients’ illnesses but are also constantly monitoring whether their treatment regimen is doing more help than harm. Our mission is to improve the quality of life of patients with immune disorders through our science-based EMC therapy.